传统慢作用抗风湿药(4)
[19] Golding JR, Andrews FM, Camp V, et al. Controlled trials of penicillamine in severe rheumatoid arthritis [J]. Ann Rheum Dis, 1973, 32(4): 385-386.
[20] Choy E, Kingsley G. How do second-line agents work? [J]. Brit Med Bull, 1995, 51(2): 472-492.
[21] Carol AL, James EB, Stephen PJ, et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease [J]. Ann Intern Med, 1998, 128(12 Pt 1): 1021-1028.
[22] Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update [J]. Arthritis Res Ther. 2011, 13(5): 240-252.
[23] Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients [J]. Arthritis Rheum, 2000, 43(5): 1021-1032.
[24] Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [J]. Immunopharmacol, 2000, 47(2-3): 85-118.
[25] Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis [J]. Am J Kidney Dis, 2002, 40(3): 447-457.
[26] Tanaka K. Lguratimod (T-614): a novel disease-modifying anti-rheumatic drug [EB/OL]. [2010-01-12]. http://ent.citiz.net/extend/zh_cn/ionaMi6FO3pa8ANgKN73uad70Pc2L8jiOVF/attach/1/1338886118.32680.ws_add05/5/5?filename=496775726174696D6F6428542D36313429416E6F76656C646973656173656D6F64696679696E67616E74692D726865756D617469636472756754616E616B61526865756D61746F6C6F67795265706F7274732E6D6874.
[27] 舒强, 李兴福, 侯怀水. 艾拉莫德对骨关节炎滑膜成纤维细胞特性的影响[J].中华风湿病学杂志, 2006, 10(7): 389-392.
[28] Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis [J]. Mod Rheumatol, 2007, 17(1): 10-16.
[29] 劳志英. 青藤碱和甲氨喋呤联合治疗类风湿性关节炎[J]. 中国新药与临床杂志, 2000, 19(4): 254-256.
(收稿日期：2012-01-31), 百拇医药
[20] Choy E, Kingsley G. How do second-line agents work? [J]. Brit Med Bull, 1995, 51(2): 472-492.
[21] Carol AL, James EB, Stephen PJ, et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease [J]. Ann Intern Med, 1998, 128(12 Pt 1): 1021-1028.
[22] Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update [J]. Arthritis Res Ther. 2011, 13(5): 240-252.
[23] Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients [J]. Arthritis Rheum, 2000, 43(5): 1021-1032.
[24] Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [J]. Immunopharmacol, 2000, 47(2-3): 85-118.
[25] Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis [J]. Am J Kidney Dis, 2002, 40(3): 447-457.
[26] Tanaka K. Lguratimod (T-614): a novel disease-modifying anti-rheumatic drug [EB/OL]. [2010-01-12]. http://ent.citiz.net/extend/zh_cn/ionaMi6FO3pa8ANgKN73uad70Pc2L8jiOVF/attach/1/1338886118.32680.ws_add05/5/5?filename=496775726174696D6F6428542D36313429416E6F76656C646973656173656D6F64696679696E67616E74692D726865756D617469636472756754616E616B61526865756D61746F6C6F67795265706F7274732E6D6874.
[27] 舒强, 李兴福, 侯怀水. 艾拉莫德对骨关节炎滑膜成纤维细胞特性的影响[J].中华风湿病学杂志, 2006, 10(7): 389-392.
[28] Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis [J]. Mod Rheumatol, 2007, 17(1): 10-16.
[29] 劳志英. 青藤碱和甲氨喋呤联合治疗类风湿性关节炎[J]. 中国新药与临床杂志, 2000, 19(4): 254-256.
(收稿日期：2012-01-31), 百拇医药